DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Geldanamycin is an investigational drug.
There have been 15 clinical trials for Geldanamycin. The most recent clinical trial was a Phase 2 trial, which was initiated on July 1st 2004.
The most common disease conditions in clinical trials are Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell, and Kidney Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), Memorial Sloan Kettering Cancer Center, and Esanex Inc.
Recent Clinical Trials for Geldanamycin
|Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma||Esanex Inc.||Phase 1|
|Dose Escalation of IPI-493 in Hematologic Malignancies||Infinity Pharmaceuticals, Inc.||Phase 1|
|Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic Cancer||National Cancer Institute (NCI)||Phase 2|